Offering validated platforms for two product lines
Biovator’s CPA method is the first test of its kind and is well positioned to answer industry demands for a reliable and efficient platform that can replace conventional in vivo testing on live animals. Presently the method is patented in several countries, including Sweden, the United States and Australia. Patent applications are presently being processed for the GAPA technology.
CPA (Cytokine Profile Assay) – for the predictive identification of potential allergenicity among novel proteins.
GAPA (Gene Activation Profile Assay) – for the predictive identification of potential allergenicity among low molecular weight compounds.
Biovator has the complete competence to technically support a variety of user needs